Search
Now showing items 1-3 of 3
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
(FRONTIERS MEDIA SA, 2021-08-20)
Gastrointestinal stromal tumors (GISTs) are a subtype of soft tissue sarcoma (STS), and have become a concept of oncogenic addiction and targeted therapies.The large majority of these tumors develop after a mutation in KIT ...
Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
(TAYLOR & FRANCIS LTD, 2023-02-01)
INTRODUCTION: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Imatinib mesylate revolutionized the management of advanced/metastatic GIST, and remains the standard ...
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
(WILEY, 2021-02-01)
BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR ...